文献速递中医内科中药与中成药合理使用

肺宁颗粒预处理减轻LPS诱导小鼠肺损伤的药理与血清代谢组学证据

Pretreatment with Feining Granules Mitigates LPS-Induced Lung Injury in Mice: Pharmacological and Serum Metabolomics Evidence.
PubMed 文献 · J Ethnopharmacol · 2026-10-29

该研究基于UHPLC-HRMS分析肺宁颗粒化学成分,并在LPS刺激的RAW264.7、MLE-12细胞及BALB/c小鼠中评估其预处理效应。结果显示肺宁颗粒可降低多种炎症因子、减少细胞凋亡并减轻肺组织损伤,血清代谢组学提示脂质与能量相关改变,但因果机制与安全性待进一步研究。

要点

  • 肺宁颗粒预处理可降低LPS诱导的IL-1β、IL-6、TNF-α等炎症因子水平
  • 1 mg/mL肺宁颗粒使MLE-12细胞凋亡比例低于单用LPS组
  • 小鼠口服预处理7天可减轻LPS所致肺组织损伤,机制与安全性待验证

核心结论

  • 肺宁颗粒预处理可减轻实验性LPS诱导的肺损伤,并伴随炎症信号、血清代谢及细胞死亡相关标志物改变。
  • 其因果机制与安全性仍需进一步研究。

研究设计与样本

  • 采用UHPLC-Q Exactive Orbitrap HRMS对70%乙醇提取物进行化学成分分析,细胞实验使用水复溶肺宁颗粒。
  • 结合网络药理学与代谢组学探索候选靶点与通路。
  • 细胞实验在LPS刺激的RAW264.7与MLE-12细胞中进行。
  • 动物实验使用BALB/c小鼠,分为对照、LPS、三个肺宁颗粒剂量(0.975–3.9 g/kg/day)及地塞米松组,每组n = 10。
  • 小鼠在鼻内LPS攻击前口服预处理7天。

主要发现

  • 肺宁颗粒降低RAW264.7细胞培养上清中IL-1β、IL-6、TNF-α和亚硝酸盐浓度。
  • 1 mg/mL肺宁颗粒组MLE-12细胞凋亡百分比为7.42 ± 1.25%,低于单用LPS组的12.25 ± 1.75%(P < 0.01),且E-钙黏蛋白荧光强度更高。
  • 小鼠预处理减轻组织学肺损伤,并降低BALF中IL-1β、IL-6、TNF-α和IL-18。
  • 血清代谢组学提示脂质与能量相关候选改变,蛋白分析显示炎症与代谢信号、凋亡及焦亡相关标志物变化。

关键数值与推荐

  • 细胞凋亡比较:1 mg/mL肺宁颗粒组7.42 ± 1.25% vs 单用LPS组12.25 ± 1.75%,P < 0.01。
  • 动物实验肺宁颗粒剂量范围为0.975–3.9 g/kg/day,每组n = 10。
  • 小鼠预处理方式为口服7天后鼻内LPS攻击。

临床怎么用

  • 肺宁颗粒传统用于缓解咳嗽、促进排痰,获批用于慢性支气管炎相关咳嗽。
  • 本研究的预处理效应为实验性急性肺损伤提供参考,但尚不能直接推导临床用药方案。
  • 临床应用于急性肺损伤相关场景前需等待因果机制与安全性研究结果。

局限性

  • 原文指出因果机制与安全性需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: The Chinese patent medicine preparation Feining Granules (FNKL), formerly known as Fanhuncao Granules, is prepared from Fanhuncao, the dried aerial parts of Jacobaea cannabifolia or Jacobaea litvinovii. FNKL is traditionally used to relieve cough and promote expectoration and is approved for cough associated with chronic bronchitis. This use, together with its reported anti-inflammatory activity, provided the basis for examining FNKL in LPS-induced lung injury. AIM OF THE STUDY: To obtain a UHPLC-HRMS-based chemical profile of FNKL and assess its pretreatment effects in LPS-stimulated cells and LPS-challenged mice, extending previous FNKL research from chronic bronchitis to experimental acute lung injury. MATERIALS AND METHODS: A 70% ethanol extract was profiled by UHPLC-Q Exactive Orbitrap HRMS, whereas water-reconstituted FNKL was used in cellular experiments. Network pharmacology and metabolomics explored candidate targets and pathways. Effects were assessed in LPS-stimulated RAW264.7 and MLE-12 cells and in BALB/c mice assigned to control, LPS, three FNKL doses (0.975-3.9 g/kg/day), or dexamethasone (n = 10/group). Mice were pretreated orally for 7 days before intranasal LPS challenge. RESULTS: Sixty-six constituents were putatively annotated, mainly flavonoids, organic acids, and alkaloids. FNKL lowered IL-1β, IL-6, TNF-α, and nitrite concentrations in RAW264.7 cell culture supernatants. At 1 mg/mL, FNKL exposure was associated with a lower apoptotic-cell percentage in MLE-12 cells than in cells exposed to LPS alone (7.42 ± 1.25% vs. 12.25 ± 1.75%; P < 0.01) and higher E-cadherin fluorescence intensity. In mice, pretreatment alleviated histological lung injury and reduced BALF IL-1β, IL-6, TNF-α, and IL-18. Serum metabolomics indicated candidate lipid- and energy-related changes. Protein analyses showed changes in markers related to inflammatory and metabolic signaling, apoptosis, and pyroptosis. CONCLUSIONS: FNKL pretreatment alleviated experimental LPS-induced lung injury, accompanied by changes in inflammatory signaling, serum metabolism, and cell-death-related markers. Causal mechanisms and safety require further investigation.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Tan, Li, Zhang, et al. Pretreatment with Feining Granules Mitigates LPS-Induced Lung Injury in Mice: Pharmacological and Serum Metabolomics Evidence. J Ethnopharmacol. 2026. PMID: 42957110. doi:10.1016/j.jep.2026.122579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。